Research advances in apatinib combined with transcatheter arterial embolization in the treatment of hepatocellular carcinoma
DOI:10.3969/j.issn.1001-5256.2020.10.036
- VernacularTitle:阿帕替尼联合经肝动脉化疗栓塞术治疗肝细胞癌的研究进展
- Author:
Zemin ZHU
1
;
Zhijian ZHAO
;
Caixi TANG
Author Information
1. Department of Hepatobiliary and Pancreatosplenic Surgery, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan 412007, China
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellar;
chemoembolization, therapeutic;
apatinib
- From:
Journal of Clinical Hepatology
2020;36(10):2325-2328
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a common malignant tumor that threatens the health of all mankind, and its incidence and mortality rates keep increasing in recent years. Most patients are in the advanced stage at the time of confirmed diagnosis and are unable to undergo potential therapeutic surgery. Transcatheter arterial chemoembolization (TACE) and the anti-angiogenic drug apatinib are two palliative treatments for HCC. At present, apatinib combined with TACE is still a new treatment method for HCC in clinical practice, and there are still controversies over its efficacy and safety, which needs further studies. This article reviews the research advances in apatinib combined with TACE in the treatment of HCC.
